Sermorelin

Sermorelin is a 29-amino acid GHRH analogue representing the minimal functional fragment of endogenous growth hormone-releasing hormone, FDA-approved since 1997 for diagnosing and treating growth hormone deficiency. It binds to the GHRH receptor mimicking endogenous GHRH while remaining subject to physiological negative feedback from somatostatin, allowing pulsatile rather than constant GH release that better reflects natural hormonal rhythm. Research demonstrates sermorelin's ability to stimulate pituitary GH gene transcription, enhance lean body mass development, and preserve neuroendocrine axis function during aging.

10mg